Cav-1 expression is significantly decreased in the fibrotic area, which appears as increased expression of alpha smooth muscle actin (α-SMA), a hallmark of lung fibrosis, in alveoli after bleomycin administration for 21 days, compared to control mice (Fig. 1A). The gene discussed is CAV1; the disease is pulmonary fibrosis.